{"url_path":"/sec/chrs/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds, and Issuer Purchases of Equity Securities","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-058703-index.html","accession_number":"0001104659-26-058703","cik":"0001512762","ticker":"CHRS","issuer_name":"Coherus Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-058703-index.html","primary_entity_key":"0001512762","primary_entity_name":"Coherus Oncology, Inc."},"word_count":71,"has_tables":true,"body_markdown":"ITEM 2.              Unregistered Sales of Equity Securities and Use of Proceeds, and Issuer Purchases of Equity Securities\n\n**Issuer Purchases of Equity Securities**\n\nWe did not repurchase any of our equity securities during the first quarter ended March 31, 2026. A total of 72,078 shares were surrendered to us in the first quarter of 2026, to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.\n\n​"}